A61P 35 - Antineoplastic agents

Patents for A61P 35 - Antineoplastic agents (221,099)
11/2006
11/14/2006	US7135279 4-alpha glucotransferases; enzymes inhibitors; enantimorphs; adrenergic blocking agents; proteases; superoxide dismutases; carbonic anhydrases
11/14/2006	US7135192 Lipid, Dna complex with detectable labels
11/14/2006	US7135188 Methods and compositions for immunotherapy of cancer
11/14/2006	US7135177 Immunoliposomes that optimize internalization into target cells
11/14/2006	US7135162 Agent for diagnosing and treating malignant tumors
11/14/2006	CA2342271C Gem substituted hydroxamic acids
11/14/2006	CA2171836C Crystalline anhydrous mycophenolate mofetil and intravenous formulation thereof
11/13/2006	CA2790058A1 Herceptin® adjuvant therapy
11/13/2006	CA2540547A1 Herceptin adjuvant therapy
11/09/2006	WO2006119211A2 Methods and compositions for treating ocular disorders
11/09/2006	WO2006119154A1 Use of pyrimidylamimobenzamide derivatives for the treatment of systematic mastocytosis
11/09/2006	WO2006118941A1 Methods of supressing uv light-induced skin carcinogenesis
11/09/2006	WO2006118749A1 Thia-tetraazaacenaphthylene kinase inhibitors
11/09/2006	WO2006118328A1 Degranulation inhibitor
11/09/2006	WO2006118313A1 Novel polypeptide and use thereof
11/09/2006	WO2006118278A1 Temperature-sensitive liposome and temperature-sensitive drug release system
11/09/2006	WO2006118256A1 2-aminoquinazoline derivatives
11/09/2006	WO2006118231A1 Cyanopyridine derivative and use thereof as medicine
11/09/2006	WO2006118131A1 Peptide having anti-anxiety effect and method for screening thereof
11/09/2006	WO2006117670A1 2-amido-6-amino-8-oxopurine derivatives as toll-like receptor modulators for the treatment of cancer and viral infections, such as hepatitis c
11/09/2006	WO2006117573A1 Combination therapy
11/09/2006	WO2006117570A1 Quinoline derivatives as kinase enzyme inhibitors
11/09/2006	WO2006117560A1 Pyrazolyl-amino- substituted pyrimidines and their use in the treatment of cancer
11/09/2006	WO2006117552A1 Quinoline and quinoxaline derivatives as inhibitors of kinase enzymatic activity
11/09/2006	WO2006117549A1 Enzyme inhibitors
11/09/2006	WO2006117548A1 Hydroxamic acid dervicatives as inhibitors of hdac enzymatic activity
11/09/2006	WO2006117523A1 Quinazoline derivatives as egf and/or erbb2 tyrosine kinase inhibitors
11/09/2006	WO2006117521A1 Quinazoline derivatives as inhibitors of egf and/or erbb2 receptor tyrosine kinase
11/09/2006	WO2006117400A2 Use of low doses of oligonucleotides antisense to tgf-beta, vegf, interleukin-10, c-jun, c-fos or prostaglandin e2 genes in the treatment of tumors
11/09/2006	WO2006117220A2 Method of administering a cationic liposomal preparation comprising paclitaxel
11/09/2006	WO2006117217A2 Novel use of spiegelmers
11/09/2006	WO2006117197A1 Antitumoral tetrahydro-pyrimidines
11/09/2006	WO2006117185A1 Pyrimidylaminobenzamide derivatives for hypereosinophilic syndrome
11/09/2006	WO2006117076A1 Use of indolin-phenylsulfonamide derivatives
11/09/2006	WO2006117075A1 Use of indolin-phenylsulfonamide derivatives
11/09/2006	WO2006116897A1 Diterpenes from euphorbia kansui and their use
11/09/2006	WO2006097337A9 11β-HYDROXYSTEROID DEHYDROGENASES
11/09/2006	WO2006096491A9 Anti-ctla-4 antibody compositions
11/09/2006	WO2006094704A3 Natural ligand of g protein coupled receptor rcc356 and uses thereof
11/09/2006	WO2006074293A3 Bicyclic dihydropyrimidines as eg5 inhibitors
11/09/2006	WO2006070432B1 Anti-tumoral immunogenic peptides and vaccine thereof
11/09/2006	WO2006063033A3 Aryl amide sphingosine 1-phosphate analogs
11/09/2006	WO2006019327B1 Deuterium depleted water (ddw) using as adjuvant in cancer therapy for cytostatics toxicity reduction
11/09/2006	WO2005074989A3 Combination of a dna topoisomerase inhibitor and an iap inhibitor
11/09/2006	WO2005049091A3 Antibody-targeted nanoparticulate active agent delivery
11/09/2006	US20060252943 Chemical process
11/09/2006	US20060252839 Cyclopenteneones for antiischemic agents, antiinflammatory agents and aging resistance
11/09/2006	US20060252810 e.g. 5-(4-Fluorophenyl)-4-(4-pyridinyl)imidazole-2-thio-3-propyl-N-phthalimide; immunomodulating and cytokine-release-inhibiting action; antiinflammatory agent
11/09/2006	US20060252799 Benzo (F) insoindol derivatives and their use as EP4 receptor ligands
11/09/2006	US20060252792 Immunology for viral diseases and biosynthesis of cytokines of anticancer drugs for tumors
11/09/2006	US20060252766 Methods using a combination of 3-heteroaryl-2-indolinone and a cyclooxygenase-2 inhibitor for the treatment of neoplasia
11/09/2006	US20060252763 Treatment of von hippel lindau disease
11/09/2006	US20060252760 Farnesyl transferase inhibitors
11/09/2006	US20060252716 Method for reversing the immunosuppressive effects of the melanoma inhibitory activity "mia"
11/09/2006	US20060252703 Method for treating cancer
11/09/2006	US20060252690 Factor VII or VIIa - Like Molecules
11/09/2006	US20060252689 Blood coagulation factor; nucleotide sequence encodes polypeptide; amino acid sequence differs in 1-15 amino acid residues and comprises an introduced in vivo N-glycosylation site; substitution V253N; coagulation related disorders
11/09/2006	US20060252676 Analgesic antitumor peptide from scorpion and method of producing it
11/09/2006	US20060252157 Larynx carcinoma-associated protein larcap-1
11/09/2006	US20060252127 Blood coagulation factor; nucleotide sequence encodes polypeptide; amino acid sequence differs in 1-15 amino acid residues and comprises an introduced in vivo N-glycosylation site; substitution V253N; coagulation related disorders
11/09/2006	US20060252037 Expression vector comprising antisense nuclelotide sequence which decrease exxpression from kinase suppressor of RAS (KRAS) for use in the treatment and prevention of cell proliferative disorders
11/09/2006	US20060252035 Using sphingosine kinase-2 as tool in identifying modulators for use in treatment of cell proliferative disorders
11/09/2006	US20060251751 Sophoridine and its use as an analgesic
11/09/2006	US20060251738 Rock flour, especially dolomite-based medicament, for the treatment of cancer diseases
11/09/2006	US20060251713 Amino acid sequences capable of facilitating penetration across a biological barrier
11/09/2006	US20060251666 Cancer antigens and utilization thereof
11/09/2006	US20060251665 Vaccines
11/09/2006	US20060251663 Employment of rotavirus proteins, derived proteins and peptides for the modulation of tisssue permeability
11/09/2006	US20060251653 Methods for treating interleukin-6 related diseases
11/09/2006	US20060251651 Antagonist and agonist which bind to a strong binding site of chemokine receptor
11/09/2006	US20060251638 Cytoprotection through the use of hif hydroxylase inhibitors
11/09/2006	US20060251635 Lactobacillus rhamnosus polynucleotides, polypeptides and methods for using them
11/09/2006	US20060251579 Medicament for the two-step perioperative therapy of solid tumours
11/09/2006	US20060251578 Therapeutic and diagnostic compounds, compositions, and methods
11/09/2006	DE102005020882A1 Use of gaboxadol and its derivatives as kinase inhibitor for the treatment of e.g. kinase induced disease, cancer, age-related macular degeneration, diabetic retinopathy and angiogenesis
11/09/2006	CA2609791A1 Botanical anticancer formulations
11/09/2006	CA2609561A1 Polypeptide, vaccine and use thereof
11/09/2006	CA2607780A1 Purine derivatives
11/09/2006	CA2607727A1 Cyanopyridine derivative and use thereof as medicine
11/09/2006	CA2607556A1 C-linked glucoronide of n-(4-hydroxybenzyl) retinone, analogs thereof, and method of using the same to inhibit neoplastic cell growth
11/09/2006	CA2607185A1 Intracellular active agents
11/09/2006	CA2606989A1 Vascular targeting of ocular neovascularization
11/09/2006	CA2606716A1 Use of pyrimidylaminobenzamide derivatives for the treatment of systematic mastocytosis
11/09/2006	CA2606382A1 Methods of supressing uv light-induced skin carcinogenesis
11/09/2006	CA2606338A1 Quinoline and quinoxaline derivatives as inhibitors of kinase enzymatic activity
11/09/2006	CA2606177A1 Novel polypeptide and use thereof
11/09/2006	CA2606162A1 Peptide having antianxiety activity and screening method therefor
11/09/2006	CA2606068A1 Pyrimidylaminobenzamide derivatives for hypereosinophilic syndrome
11/09/2006	CA2605784A1 Antitumoral tetrahydro-pyrimidines
11/09/2006	CA2601067A1 Method of administering a cationic liposomal preparation comprising paclitaxel
11/09/2006	CA2599411A1 Enzyme inhibitors
11/09/2006	CA2591586A1 Use of low doses of oligonucleotides antisense to tgf-beta, vegf, interleukin-10, c-jun, c-fos or prostaglandin e2 genes in the treatment of tumors
11/08/2006	EP1719780A2 Mammalian cytokine-like polypeptide-10
11/08/2006	EP1719779A2 Antibodies against Matin
11/08/2006	EP1719775A1 Camptothecins with a modified lactone ring
11/08/2006	EP1719771A1 Pyrazoloquinolone derivative and use thereof
11/08/2006	EP1719763A1 Novel pyridine derivative and pyrimidine derivative (2)
11/08/2006	EP1719762A1 Novel pyridine derivative and pyrimidine derivative (1)
11/08/2006	EP1719757A1 Bicyclo derivative
11/08/2006	EP1719528A2 Compositions and methods for treatment of angiogenesis in pathological lesions

1 ... 1136 1137 1138 1139 1140 1141 1142 1143 1144 1145 1146 1147 1148 1149 1150 1151 1152 1153 1154 1155 1156 ... 2211